National and Kapodistrian University of Athens
Cancer biomarkers for immune and targeted therapy
Abstract
dc:descriptionPURPOSE Analyzing biomarkers in cancer offers insights that go beyond traditional clinical factors, helping to identify patients who are likely to have a more favorable balance of benefits and risks with specific treatments. This biomarker study centers on two types of epithelial cancers: Head and Neck Squamous Cell Carcinoma (HNSCC) and Breast Cancer (BC). PATIENTS AND METHODS Samples from forty-one HNSCC patients that were randomized to Cisplatin plus Olaparib (Arm A), Olaparib alone (Arm B), no treatment (Arm C) or Durvalumab plus Olaparib (Arm D) were used to evaluate for pre-specified biomarkers. Cell lines and tissue microarrays (TMAs) were used to examine the dynamic range of HER2 biomarker and develop an assay specific to low HER2 expression and then to determine the prevalence of low-level expression in each specimen from a serial, retrospective collection of breast cancer cases. RESULTSA reduction in Ki67 by at least 25% was detected in 44.8% of patients receiving treatment, as determined through quantitative immunofluorescence (QIF). Post-treatment, PD-L1 levels (measured by Combined Positive Score) were notably elevated in groups (A) and (D). There was a significant increase in the expression of CD163 and Colony Stimulating Factor 1 Receptor (CSF1R) genes—markers associated with M2 macrophages—while the expression of CD80, an M1 macrophage marker, decreased. Through calculations of detection limits, quantification, and assay linearity, we established that the expression range of HER2 in non-amplified cell lines lies between 2 and 20 attomol/mm². CONCLUSION Treatment with olaparib influences the tumor microenvironment by increasing PD-L1 levels and promoting pro-tumor characteristics in macrophages. When this assay was applied to a sequential cohort of 364 breast cancer cases from Yale, results showed that 67% of the cases had HER2 expression above the quantification limit but below the levels typical of HER2-amplified breast cancer.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Moutafi, Myrto
- Μουτάφη, Μυρτώ
Subjects
dc:subject × 16- Μεταφραστικοί βιοδείκτες
- Kαρκίνος μαστού
- Kαρκίνος κεφαλής και τραχήλου
- Aξιολόγηση HER2
- Aναστολή PARP
- Translational biomarkers
- Breast cancer
- Head and neck cancer
- HER2 assessment
- PARP inhibition
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ογκολογία
- Clinical Medicine
- Medical and Health Sciences
- Oncology
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58406